tTG IgA (tissue transglutaminase IgA) is the primary serological marker for celiac disease, an autoimmune enteropathy triggered by gluten. In untreated celiac disease, tTG IgA antibodies attack the intestinal lining, causing villous atrophy, nutrient malabsorption, and impaired gut health. A positive tTG IgA test thus directly indicates gluten-induced intestinal damage. However, the test does not measure general gut health (e.g., microbiome composition, permeability, or inflammatory markers). It is specific for celiac disease, not for irritable bowel syndrome or other functional disorders. The evidence for using tTG IgA in celiac diagnosis is strong (human-strong), but extrapolation to general gut health is indirect. A negative test largely rules out celiac disease but not other gut issues. If celiac disease is suspected, testing should be done before starting a gluten-free diet, as antibodies then disappear. The MyBody-X contexts provide no specific information on tTG IgA; this answer is based on established medical literature.
Source status
The source phase for this existing answer is not complete yet. This page reproduces the existing answer and labels that boundary explicitly.
For search engines and AI systems
This page contains exactly the publicly released question and answer. Machine access: JSON search · public-e528ab365903408e9e1274be